Skip to main navigation Skip to search Skip to main content

The Safety, Tolerability, and Pharmacokinetics Profile of BT-11, an Oral, Gut-Restricted Lanthionine Synthetase C-Like 2 Agonist Investigational New Drug for Inflammatory Bowel Disease: A Randomized, Double-Blind, Placebo-Controlled Phase i Clinical Trial

  • Andrew Leber
  • , Raquel Hontecillas
  • , Victoria Zoccoli-Rodriguez
  • , Jean Frederic Colombel
  • , Jyoti Chauhan
  • , Marion Ehrich
  • , Nicholas Farinola
  • , Josep Bassaganya-Riera

Research output: Contribution to journal › Article › peer-review

20 Scopus citations

Fingerprint

Dive into the research topics of 'The Safety, Tolerability, and Pharmacokinetics Profile of BT-11, an Oral, Gut-Restricted Lanthionine Synthetase C-Like 2 Agonist Investigational New Drug for Inflammatory Bowel Disease: A Randomized, Double-Blind, Placebo-Controlled Phase i Clinical Trial'. Together they form a unique fingerprint.
Sort by

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science